Skip to content
PBYIPuma Biotechnology, Inc.

Earnings

When Puma Biotechnology, Inc. reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, after the close

Thu, Feb 25, 2027in 100 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 24 – Mar 5

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$75.45M
Revenue, change from a year earlier: Q3 2026 +1.1%, Q2 2026 +7.8%, Q1 2026 −2.6%, Q4 2025 +27.7%
Net income
$13.44M
Net income, change from a year earlier: Q3 2026 −32.7%, Q2 2026 +39.9%, Q1 2026 n/m, Q4 2025 −30.4%
EPS
—
EPS, change from a year earlier: Q3 2026 −35.3%, Q2 2026 +33.3%, Q1 2026 n/m, Q3 2025 −58.5%

Quarter by quarter

Q3 2026$55.06M+1.1% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, after the closeThe release15.6%by the close of Nov 6
    Revenue
    $55.06M
    +1.1%
    Net income
    $5.96M
    −32.7%
    EPS
    $0.11
    −35.3%
    On November 5, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026.
  2. Q2 2026Aug 6, 2026, after the closeThe release+10.0%by the close of Aug 7
    Revenue
    $56.50M
    +7.8%
    Net income
    $8.19M
    +39.9%
    EPS
    $0.16
    +33.3%
  3. Q1 2026May 7, 2026, after the closeThe release+3.5%by the close of May 8
    Revenue
    $44.81M
    −2.6%
    Net income
    -$3.75M
    N/M
    EPS
    -$0.07
    N/M
  4. Q4 2025Feb 26, 2026, after the closeThe release24.9%by the close of Feb 27
    Revenue
    $75.45M
    +27.7%
    Net income
    $13.44M
    −30.4%
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · after-hoursNov 9, 202640 d10-Q$55.06M+1.1%$0.1115.6%
Q2 2026Jun 30, 2026Aug 6, 2026 · after-hoursAug 6, 202637 d10-Q$56.50M+7.8%$0.16+10.0%
Q1 2026Mar 31, 2026May 7, 2026 · after-hoursMay 7, 202637 d10-Q$44.81M−2.6%-$0.07+3.5%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · after-hoursFeb 26, 202657 d10-K$75.45M+27.7%—24.9%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q$54.48M−32.4%$0.17+22.1%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$52.44M+11.4%$0.12+12.1%
Q1 2025Mar 31, 2025May 8, 2025 · after-hoursMay 8, 202538 d10-Q$46.01M+5.1%$0.064.3%
FY 2024
Q4 2024derivedDec 31, 2024Feb 27, 2025 · after-hoursFeb 27, 202558 d10-K$59.08M−18.2%—+20.1%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$80.54M+43.5%$0.414.3%
Q2 2024Jun 30, 2024Aug 1, 2024 · after-hoursAug 1, 202432 d10-Q$47.08M−13.7%-$0.09+9.4%
Q1 2024Mar 31, 2024May 2, 2024 · after-hoursMay 2, 202432 d10-Q$43.77M−17.1%-$0.10—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026035912
10-QAug 6, 2026026311
10-QMay 7, 2026015633
10-KFeb 26, 2026005891
10-QNov 6, 2025033633
10-QAug 7, 2025025470
10-QMay 8, 2025015533
10-KFeb 27, 2025005496
10-QNov 7, 2024033955
10-QAug 1, 2024024309

Provenance

ProvenanceData status and checks

Puma Biotechnology, Inc. · CIK 1401667 · Engraved from SEC EDGAR